64x Bio
Enabling next generation medicines. A comprehensive platform and…
What they do
Next generation therapies are limited by manufacturing constraints that prevent them from scaling efficiently.
VectorSelect is a platform that uses massively parallel screens and computational insights to engineer high-yield cell lines and production technologies for advanced therapy manufacturing.
Biopharma and advanced therapy developers needing scalable manufacturing for gene and cell therapies.
Founders
Lexi Rovner, PhD is the CEO & co-founder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute. Lexi completed her PhD at Yale University and her postdoctoral work in George Church’s lab at Harvard Medical School, where she co-founded the company alongside George, Pam Silver, Jeff Way, and David Thompson. Lexi is a Y Combinator alum, a 2022 Endpoints 20 under 40 Next-Generation Biotech Leader, and a 2022 Bloomberg New Economy Catalyst Awardee.
Company timeline
- Founded2017
- YC batchSummer 2018
- StatusActive
- Team size25 people
- LocationSan Francisco, CA, USA
Similar startups
